Evidence map›Paper›PMID 26114663›Full record

ArticlePloS one2015

Association between Dopamine Receptor D2 (DRD2) Variations rs6277 and rs1800497 and Cognitive Performance According to Risk Type for Psychosis: A Nested Case Control Study in a Finnish Population Sample.

Hugh Ramsay, Jennifer H Barnett, Jouko Miettunen, Sari Mukkala, Pirjo Mäki, Johanna Liuhanen, Graham K Murray, Marjo-Riitta Jarvelin, Hanna Ollila, Tiina Paunio and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. The effect ofBrain and behavior · 2017
    Article
  8. Article
  9. Observational
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 3 countries.

Hugh RamsayDepartment of Psychiatry, Centre for Clinical Neuroscience, University of Oulu, Oulu, Finland; Health Service Executive, Dublin, Ireland.
Jennifer H BarnettDepartment of Psychiatry, University of Cambridge, Cambridge Biomedical Campus, Cambridge, United Kingdom; Cambridge Cognition Ltd., Bottisham, Cambridge, United Kingdom.
Jouko MiettunenDepartment of Psychiatry, Centre for Clinical Neuroscience, University of Oulu, Oulu, Finland; Institute of Health Sciences, University of Oulu, Oulu, Finland; Medical Research Center Oulu, University of Oulu and Oulu University Hospital, Oulu, Finland.
Sari MukkalaDepartment of Psychiatry, Oulu University Hospital, Oulu, Finland.
Pirjo MäkiDepartment of Psychiatry, Centre for Clinical Neuroscience, University of Oulu, Oulu, Finland; Department of Psychiatry, Oulu University Hospital, Oulu, Finland; Department of Psychiatry, Länsi-Pohja healthcare district, Finland; Department of Psychiatry, the Middle Ostrobothnia Central Hospital, Kiuru, Finland; Mental health services, Joint Municipal Authority of Wellbeing in Raahe District, Finland; Mental health services, Basic Health Care District of Kallio, Finland; Visala Hospital, the Northern Ostrobothnia Hospital District, Finland.
Johanna LiuhanenPublic Health Genomics Unit, National Institute for Health and Welfare and Institute for Molecular Medicine, Helsinki, Finland.
Graham K MurrayDepartment of Psychiatry, University of Cambridge, Cambridge Biomedical Campus, Cambridge, United Kingdom.
Marjo-Riitta JarvelinDepartment of Public Health Science and General Practice, Institute of Health Sciences, University of Oulu, Oulu, Finland; Faculty of Medicine, School of Public Health, Imperial College London, London, United Kingdom.
Hanna OllilaPublic Health Genomics Unit, National Institute for Health and Welfare and Institute for Molecular Medicine, Helsinki, Finland.
Tiina PaunioPublic Health Genomics Unit, National Institute for Health and Welfare and Institute for Molecular Medicine, Helsinki, Finland; Department of Psychiatry, Institute of Clinical Medicine, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland.
Juha VeijolaDepartment of Psychiatry, Centre for Clinical Neuroscience, University of Oulu, Oulu, Finland; Department of Psychiatry, Oulu University Hospital, Oulu, Finland.
University of Oulu · FIInstitute for Molecular Medicine Finland · FIUniversity of Cambridge · GBOulu University Hospital · FIUniversity of Helsinki · FI

Funding

Medical Research Council G0701911
6 · The paper itself

Abstract

backgroundThere is limited research regarding the association between genes and cognitive intermediate phenotypes in those at risk for psychotic disorders.

methodsWe measured the association between established psychosis risk variants in dopamine D2 receptor (DRD2) and cognitive performance in individuals at age 23 years and explored if associations between cognition and these variants differed according to the presence of familial or clinical risk for psychosis. The subjects of the Oulu Brain and Mind Study were drawn from the general population-based Northern Finland 1986 Birth Cohort (NFBC 1986). Using linear regression, we compared the associations between cognitive performance and two candidate DRD2 polymorphisms (rs6277 and rs1800497) between subjects having familial (n=61) and clinical (n=45) risk for psychosis and a random sample of participating NFBC 1986 controls (n=74). Cognitive performance was evaluated using a comprehensive battery of tests at follow-up.

resultsPrincipal components factor analysis supported a three-factor model for cognitive measures. The minor allele of rs6277 was associated with poorer performance on a verbal factor (p=0.003) but this did not significantly interact with familial or clinical risk for psychosis. The minor allele of rs1800497 was associated with poorer performance on a psychomotor factor (p=0.038), though only in those at familial risk for psychotic disorders (interaction p=0.049).

conclusionThe effect of two DRD2 SNPs on cognitive performance may differ according to risk type for psychosis, suggesting that cognitive intermediate phenotypes differ according to the type (familial or clinical) risk for psychosis.

Indexed as

AllelesCognitionPolymorphism, Single NucleotideAdultCase-Control StudiesFemaleFinlandGenotypeHumansMalePsychomotor PerformancePsychotic DisordersReceptors, Dopamine D2Risk FactorsYoung AdultReceptors, Dopamine D2

Identifiers

PMID26114663
PMCPMC4482687
OpenAlexW1588007205

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.